

Rosaria Talarico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9225341/publications.pdf>

Version: 2024-02-01

88
papers

1,961
citations

257429

24
h-index

276858

41
g-index

91
all docs

91
docs citations

91
times ranked

3136
citing authors

#	ARTICLE	IF	CITATIONS
1	Classification criteria for Sjogren's syndrome: A critical review. <i>Journal of Autoimmunity</i> , 2012, 39, 9-14.	6.5	122
2	The diagnosis and classification of mixed connective tissue disease. <i>Journal of Autoimmunity</i> , 2014, 48-49, 46-49.	6.5	101
3	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , 2016, 35, 1281-1286.	2.2	95
4	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	3.8	91
5	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	3.5	89
6	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 380.	3.5	72
7	COVID-19: the new challenge for rheumatologists. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 175-180.	0.8	69
8	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	3.8	66
9	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2018, 37, 2233-2240.	2.2	64
10	Behçet's syndrome: a critical digest of the 2014-2015 literature. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S3-14.	0.8	63
11	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 277.	3.5	55
12	A Clinical Prediction Rule for Lymphoma Development in Primary Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2012, 39, 804-808.	2.0	48
13	Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. <i>Lancet Rheumatology</i> , The, 2020, 2, e518-e519.	3.9	44
14	Relapsing polychondritis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000788.	3.8	43
15	Behçet's syndrome: a critical digest of the 2013-2014 literature. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S112-22.	0.8	40
16	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1098-1104.	0.9	39
17	Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. <i>Muscle and Nerve</i> , 2016, 54, 666-672.	2.2	38
18	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38

#	ARTICLE	IF	CITATIONS
19	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
20	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	8.0	35
21	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	3.8	34
22	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. <i>Medicine (United States)</i> , 2015, 94, e1858.	1.0	31
23	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	3.8	30
24	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	3.8	28
25	Vitamin D in early primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?. <i>Rheumatology International</i> , 2014, 34, 1159-1164.	3.0	27
26	One year in review 2016: spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 3-17.	0.8	27
27	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	3.5	25
28	Successful Treatment of Refractory Adult-Onset Still Disease With Canakinumab. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 121.	0.9	24
29	One year in review 2017: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 721-734.	0.8	24
30	Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000790.	3.8	23
31	The interaction between autoimmune diseases and fibromyalgia: risk, disease course and management. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1069-1076.	3.0	22
32	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	22
33	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 103-108.	1.9	22
34	IgG4-related diseases: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000787.	3.8	21
35	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	2.6	21
36	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	3.8	19

#	ARTICLE	IF	CITATIONS
37	Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin?. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S55-8.	0.8	19
38	Epidemiology and Management of Neuropsychiatric Disorders in Behçet's Syndrome. <i>CNS Drugs</i> , 2015, 29, 189-196.	5.9	18
39	One year in review 2016: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 357-72.	0.8	17
40	One year in review 2016: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 10-22.	0.8	16
41	Differential impact of high and low penetrance <i>TNFRSF1A</i> gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. <i>Journal of Leukocyte Biology</i> , 2016, 99, 761-769.	3.3	15
42	COVID-19: the new challenge for rheumatologists. First update. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 373-382.	0.8	15
43	RareRN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 347.	2.7	12
44	One year in review 2019: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 3-17.	0.8	12
45	Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies. <i>RMD Open</i> , 2021, 7, e001914.	3.8	12
46	One year in review: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 102-8.	0.8	11
47	One year in review 2017: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 3-15.	0.8	11
48	Sexual dysfunction in Behçet's syndrome. <i>Rheumatology International</i> , 2020, 40, 9-15.	3.0	10
49	Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S130-8.	0.8	10
50	Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis. <i>Medicine (United States)</i> , 2015, 94, e1170.	1.0	9
51	Development of de novo major involvement during follow-up in Behçet's syndrome. <i>Clinical Rheumatology</i> , 2016, 35, 247-250.	2.2	9
52	Shaping the Future of Rare Diseases after a Global Health Emergency: Organisational Points to Consider. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8694.	2.6	9
53	One year in review 2018: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 12-32.	0.8	9
54	One year in review 2018: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 13-27.	0.8	9

#	ARTICLE	IF	CITATIONS
55	One year in review 2021: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.8	9
56	Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study. <i>Clinical Rheumatology</i> , 2013, 32, 1547-1548.	2.2	7
57	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014, 5, 95-100.	3.9	6
58	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , 2020, 6, e001344.	3.8	6
59	Behçet's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 125-128.	0.8	6
60	One year in review 2020: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 3-10.	0.8	6
61	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 769870.	2.6	6
62	Systemic vasculitis and the lung. <i>Current Opinion in Rheumatology</i> , 2017, 29, 45-50.	4.3	5
63	Behçet's syndrome and ocular involvement: changes over time. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 86-93.	0.8	5
64	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 203-213.	0.8	5
65	A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	4
66	One year in review 2019: vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 3-19.	0.8	4
67	Being a caregiver of a Behçet's syndrome patient: challenges and perspectives during a complex journey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 436.	2.7	3
68	One year in review 2017: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 5-26.	0.8	3
69	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.8	3
70	One year in review 2020: vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 3-14.	0.8	2
71	One year in review 2021: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 3-12.	0.8	2
72	COVID-19 mRNA vaccine booster in patients with autoimmune rheumatic diseases. <i>Rheumatology</i> , 2022, 61, e328-e330.	1.9	2

#	ARTICLE	IF	CITATIONS
73	Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: A prospective observational study. <i>Joint Bone Spine</i> , 2014, 81, 378-379.	1.6	1
74	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 203-213.	0.8	1
75	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 3-13.	0.8	1
76	Empowering rare disease patients through patient education: the new BehçetTalk programme. <i>BMC Rheumatology</i> , 2022, 6, 17.	1.6	1
77	Systemic vasculitis: one year in review 2022. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 673-687.	0.8	1
78	An Opportunity to Harmonise the Approach to Patients' Care Pathways for Rare and Complex Diseases: RarERN Pathway, 0, 2, .		1
79	Taux d'infections sévères chez les patients atteints de polyarthrite rhumatoïde recevant une biothérapie anti-TNF alpha: Étude observationnelle prospective. Commentaire de l'article de Che et al.. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 66-67.	0.0	0
80	Morphologic ultrasonography of the temporal artery for diagnosis of giant cell arteritis: Brief report. <i>Modern Rheumatology</i> , 2019, 29, 717-719.	1.8	0
81	Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center. <i>Clinical Rheumatology</i> , 2019, 38, 2917-2923.	2.2	0
82	AB0618...A SNAPSHOT OF DISEASE ACTIVITY IN PATIENTS WITH BEHCET'S SYNDROME: PREDICTIVE FACTORS AND RELATIONSHIP WITH QUALITY OF LIFE. , 2019, , .		0
83	FRIO607...IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
84	Skin Manifestations and Cryoglobulinemia. , 2014, , 329-335.		0
85	Behçet Disease. , 2016, , 225-232.		0
86	Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1036-1043.	0.8	0
87	Adherence to treatment in Behçet's syndrome: a multi-faceted issue. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 88-93.	0.8	0
88	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0